Xeris Biopharma Holdings, Inc. (XERS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$10.20-6.08%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Xeris Biopharma Holdings, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	111.02M
EPS	—	0.052
Annual ending 2026-12-31
Revenue	—	387.9M
EPS	—	0.005
Annual ending 2027-12-31
Revenue	—	480.03M
EPS	—	0.344

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage convertible notes via exchange agreements	A supporting condition in Xeris Biopharma Holdings, Inc.'s published investment case. The stated target is Execute exchange agreements for $23 million principal in 2026-Q2.	Intact	Fail to execute or reverse exchange agreements in 2026-Q2	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management completed privately negotiated exchange agreements that eliminated approximately $23 million of debt through cash and stock issuance. This action reflects active capital allocation management to strengthen the balance sheet. No prior quarters mention this, so progress is recent and specific. Delivery assessment Oct 24, 2026
Achieve and sustain positive net income	Net income turned positive at $2.2 million in 2026-Q1.	Broken	Net income falls below zero over next 4 quarters	Net income: $-31.101M FY2026-Q2; GAAP. Published target: > 0 net income. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-31,101,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e8370248-aafd-438c-b6ea-e9908be2437b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Raise and deliver full-year 2026 revenue guidance	A primary condition in Xeris Biopharma Holdings, Inc.'s published investment case. The stated target is >= $380 million.	Intact	Revenue falls below $380 million in FY26	Revenue: $92.1M FY2026-Q2; GAAP. Published target: >= $380 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 202692,100,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e8370248-aafd-438c-b6ea-e9908be2437b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management raised and then tightened full-year 2026 revenue guidance from $380–$390 million in Q1 to $385–$390 million in Q2. Total revenue grew from $83.1 million in 2026-Q1 to $92.1 million in 2026-Q2, driven by strong product revenue growth, especially Recorlev. The trajectory is delivering consistent growth and management confidence. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.48B

$0.47B → $0.48B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$472,383,333	4 / 5
2026-07-25	Unavailable	$472,383,330	4 / 6
2026-07-26	Unavailable	$472,383,330	4 / 6
2026-07-27	Unavailable	$472,383,333	4 / 5
2026-07-28	Unavailable	$472,383,333	4 / 5
2026-07-29	Unavailable	$472,383,330	4 / 6
2026-07-30	Unavailable	$472,383,330	4 / 6
2026-07-31	Unavailable	$472,383,333	4 / 5
2026-08-01	Unavailable	$472,383,333	4 / 5
2026-08-02	Unavailable	$472,383,333	4 / 5
2026-08-03	Unavailable	$472,383,330	4 / 6
2026-08-04	Unavailable	$472,383,330	4 / 6
2026-08-05	Unavailable	$472,383,333	4 / 5
2026-08-06	Unavailable	$472,383,330	4 / 6
2026-08-08	Unavailable	$472,383,333	4 / 5
2026-08-09	Unavailable	$472,383,333	4 / 5
2026-08-10	Unavailable	$474,950,000	3 / 6
2026-08-12	Unavailable	$472,383,333	4 / 5
2026-08-13	Unavailable	$480,700,000	3 / 6
2026-08-14	Unavailable	$472,383,333	4 / 5
2026-08-15	Unavailable	$472,383,333	4 / 5
2026-08-16	Unavailable	$472,383,333	4 / 5
2026-08-17	Unavailable	$472,383,333	4 / 5
2026-08-18	Unavailable	$472,383,333	4 / 5
2026-08-19	Unavailable	$472,383,333	4 / 5
2026-08-20	Unavailable	$480,700,000	4 / 5
2026-08-21	Unavailable	$480,700,000	4 / 5
2026-08-22	Unavailable	$480,700,000	4 / 5
2026-08-23	Unavailable	$480,700,000	4 / 5
2026-08-24	Unavailable	$480,700,000	4 / 5
2026-08-25	Unavailable	$480,700,000	4 / 5
2026-08-26	Unavailable	$480,700,000	4 / 5
2026-08-27	Unavailable	$480,700,000	4 / 5
2026-08-28	Unavailable	$480,700,000	4 / 5
2026-08-29	Unavailable	$480,700,000	4 / 5
2026-08-30	Unavailable	$480,700,000	4 / 5
2026-08-31	Unavailable	$480,700,000	4 / 5
2026-09-01	Unavailable	$480,700,000	4 / 5
2026-09-02	Unavailable	$480,700,000	4 / 5
2026-09-03	Unavailable	$480,700,000	4 / 5
2026-09-04	Unavailable	$480,700,000	4 / 5
2026-09-05	Unavailable	$480,700,000	4 / 5
2026-09-06	Unavailable	$480,700,000	4 / 5
2026-09-07	Unavailable	$480,700,000	4 / 5
2026-09-08	Unavailable	$480,700,000	4 / 5
2026-09-09	Unavailable	$480,700,000	4 / 5
2026-09-10	Unavailable	$480,700,000	4 / 5
2026-09-11	Unavailable	$480,700,000	4 / 5
2026-09-12	Unavailable	$480,700,000	4 / 5
2026-09-13	Unavailable	$480,700,000	4 / 5
2026-09-14	Unavailable	$480,700,000	4 / 5
2026-09-15	Unavailable	$480,700,000	4 / 5
2026-09-16	Unavailable	$480,700,000	4 / 5
2026-09-17	Unavailable	$480,700,000	4 / 5
2026-09-18	Unavailable	$480,700,000	4 / 5
2026-09-19	Unavailable	$480,700,000	4 / 5
2026-09-20	Unavailable	$480,700,000	4 / 5
2026-09-21	Unavailable	$480,700,000	4 / 5
2026-09-22	Unavailable	$480,700,000	4 / 5
2026-09-23	Unavailable	$480,700,000	4 / 5
2026-09-24	Unavailable	$480,700,000	4 / 5
2026-09-25	Unavailable	$480,700,000	4 / 5
2026-09-26	Unavailable	$480,700,000	4 / 5
2026-09-27	Unavailable	$480,700,000	4 / 5
2026-09-28	Unavailable	$480,700,000	4 / 5
2026-09-29	Unavailable	$480,700,000	4 / 5
2026-09-30	Unavailable	$480,700,000	4 / 5
2026-10-01	Unavailable	$480,700,000	4 / 5
2026-10-02	Unavailable	$480,700,000	4 / 5
2026-10-03	Unavailable	$480,700,000	4 / 5
2026-10-04	Unavailable	$480,700,000	4 / 5
2026-10-05	Unavailable	$480,700,000	4 / 5
2026-10-06	Unavailable	$480,700,000	4 / 5
2026-10-07	Unavailable	$480,033,333	3 / 5
2026-10-08	Unavailable	$480,033,333	4 / 5
2026-10-09	Unavailable	$480,033,333	4 / 5
2026-10-10	Unavailable	$480,033,333	4 / 5
2026-10-11	Unavailable	$480,033,333	4 / 5
2026-10-12	Unavailable	$480,033,333	4 / 5
2026-10-13	Unavailable	$480,033,333	4 / 5
2026-10-14	Unavailable	$480,033,333	4 / 5
2026-10-15	Unavailable	$480,033,333	4 / 5
2026-10-16	Unavailable	$480,033,333	4 / 5
2026-10-17	Unavailable	$480,033,333	4 / 5
2026-10-18	Unavailable	$480,033,333	4 / 5
2026-10-19	Unavailable	$480,033,333	4 / 5
2026-10-20	Unavailable	$480,033,333	4 / 5
2026-10-21	Unavailable	$480,033,333	4 / 5
2026-10-22	Unavailable	$480,033,333	4 / 5
2026-10-23	Unavailable	$480,033,333	4 / 5
2026-10-24	Unavailable	$480,033,333	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	6	1
2026-07-01	6	1
2026-08-01	6	1
2026-09-01	6	1
2026-10-01	6	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 6 · prior Aug 20

$12.00 → $14.00+16.7%

$0$7.70$15.40

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage convertible notes via exchange agreementsDirect metric needs a verified mapping
Achieve and sustain positive net incomePublished status: Broken
Raise and deliver full-year 2026 revenue guidanceRevenue: $92.1M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-46.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Xeris Biopharma Holdings, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk growth thesis, not a proven earnings compounder, because the company is still loss-making. The long-term thesis is intact, supported by strong recent financial performance, though execution remains uneven and confidence in the evidence is medium.

What's priced into Xeris Biopharma Holdings, Inc.

The valuation evidence points to a durable premium versus peers, while the model has low confidence and shows a negative expectations gap. That suggests the market already gives weight to lasting growth, but the evidence does not establish that expectations are easy to meet.

What the fundamentals likely do

Near term, revenue has grown from $83.1 million in Q1 2026 to $92.1 million in Q2, led especially by Recorlev, and management raised then tightened its 2026 revenue guidance. The next report remains a watch point: the evidence flags a 40% miss probability, and a guidance reversal would damage credibility. Over the multi-year view, XP-8121 Phase 3 progress and the expected Keveyis patent extension support development and product protection, but execution on these priorities is mixed.

What Xeris Biopharma Holdings, Inc. hinges on

The main unfavorable scenario is a guidance cut after the recent increase, which could weaken confidence in management's outlook. A weaker jobs trend could also weigh on healthcare names, while continued strong results and guidance from sector peers would support the backdrop. For the multi-year thesis, progress on XP-8121 and continued product-revenue growth are key swing factors.